A fundamental shift in the understanding, detection and treatment of prostate cancer has occurred over the past 10 years, especially in the use of screening, active surveillance, novel therapies and radical surgery. These discoveries have changed how clinicians and patients approach prostate cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Andriole, G. L. et al. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360, 1310–1319 (2009).
Schröder, F. H. et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet http://dx.doi.org/10.1016/S0140-6736(14)60525-0.
Hugosson, J. et al. Mortality results from the Göteborg randomized population-based prostate-cancer screening trial. Lancet Oncol. 11, 725–732 (2010).
Vickers, A. J. et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40–55 and long term risk of metastasis: case-control study. BMJ 2013, 346–357 (2013).
Sanda, M. G. et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N. Engl. J. Med. 358, 1250–1261 (2008).
Gandaglia, G. et al. Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. J. Clin. Oncol. 32, 1419–1426 (2014).
Vickers, A. et al. Cancer control and functional outcomes after radical prostatectomy as markers of surgical quality: analysis of heterogeneity between surgeons at a single cancer center. Eur. Urol. 59, 317–322 (2011).
Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644–648 (2005).
Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11–22 (2010).
Chen, C. D. et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33–39 (2004).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
P.T.S. is a paid scientific advisor to OPKO Diagnostics, which has licensed the 4KScore® from P.T.S. and colleagues for commercial development. B.E. declares no competing interests.
Rights and permissions
About this article
Cite this article
Ehdaie, B., Scardino, P. A decade of progress in detection and treatment. Nat Rev Urol 11, 618–620 (2014). https://doi.org/10.1038/nrurol.2014.284
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2014.284
